van Vuren Roos M G, Janssen Yester F, Hogenbirk Rianne N M, de Graaff Michelle R, van den Hoek Rinske, Kruijff Schelto, Heineman David J, van der Plas Willemijn Y, Wouters Michel W J M
Department of Surgery, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands.
Department of Neurosurgery, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands.
Cancers (Basel). 2024 Apr 29;16(9):1738. doi: 10.3390/cancers16091738.
To avoid delay in oncological treatment, a 6-weeks norm for time to treatment has been agreed on in The Netherlands. However, the impact of the COVID-19 pandemic on health systems resulted in reduced capacity for regular surgical care. In this study, we investigated the impact of the COVID-19 pandemic on time to treatment in surgical oncology in The Netherlands.
A population-based analysis of data derived from five surgical audits, including patients who underwent surgery for lung cancer, colorectal cancer, upper gastro-intestinal, and hepato-pancreato-biliary (HPB) malignancies, was performed. The COVID-19 cohort of 2020 was compared to the historic cohorts of 2018 and 2019. Primary endpoints were time to treatment initiation and the proportion of patients whose treatment started within 6 weeks. The secondary objective was to evaluate the differences in characteristics and tumour stage distribution between patients treated before and during the COVID-19 pandemic.
A total of 14,567 surgical cancer patients were included in this study, of these 3292 treatments were started during the COVID-19 pandemic. The median time to treatment decreased during the pandemic (26 vs. 27 days, < 0.001) and the proportion of patients whose treatment started within 6 weeks increased (76% vs. 73%, < 0.001). In a multivariate logistic regression analysis, adjusting for patient characteristics, no significant difference in post-operative outcomes between patients who started treatment before or after 6 weeks was found. Overall, the number of procedures performed per week decreased by 8.1% during the pandemic. This reduction was most profound for patients with stage I lung carcinoma and colorectal carcinoma. There were fewer patients with pulmonary comorbidities in the pandemic cohort (11% vs. 13%, = 0.003).
Despite pressure on the capacity of the healthcare system during the COVID-19 pandemic, a larger proportion of surgical oncological patients started treatment within six weeks, possibly due to prioritisation of cancer care and reductions in elective procedures. However, during the pandemic, a decrease in the number of surgical oncological procedures performed in The Netherlands was observed, especially for patients with stage I disease.
为避免肿瘤治疗延误,荷兰已商定治疗时间的规范为6周。然而,新冠疫情对卫生系统的影响导致常规手术护理能力下降。在本研究中,我们调查了新冠疫情对荷兰外科肿瘤学治疗时间的影响。
对来自五项手术审计的数据进行基于人群的分析,这些数据包括接受肺癌、结直肠癌、上消化道和肝胰胆(HPB)恶性肿瘤手术的患者。将2020年的新冠疫情队列与2018年和2019年的历史队列进行比较。主要终点是治疗开始时间和在6周内开始治疗的患者比例。次要目标是评估新冠疫情之前和期间接受治疗的患者在特征和肿瘤分期分布上的差异。
本研究共纳入14567例外科癌症患者,其中3292例治疗在新冠疫情期间开始。疫情期间治疗的中位时间缩短(26天对27天,<0.001),且在6周内开始治疗的患者比例增加(76%对73%,<0.001)。在多因素逻辑回归分析中,在调整患者特征后,发现6周前或6周后开始治疗的患者术后结局无显著差异。总体而言,疫情期间每周进行的手术数量减少了8.1%。这种减少在I期肺癌和结直肠癌患者中最为明显。疫情队列中肺部合并症患者较少(11%对13%,P = 0.003)。
尽管新冠疫情期间医疗系统能力面临压力,但更大比例的外科肿瘤学患者在六周内开始治疗,这可能是由于癌症护理的优先安排和择期手术的减少。然而,在疫情期间,荷兰进行的外科肿瘤手术数量有所减少,尤其是I期疾病患者。